Abstract: This application relates to carboxylate dyes suitable for use in fabric care compositions and in the treatment of fabrics.

Abstract: Disclosed herein is a way to produce a series of discrete sized slender, rigid oligoparaxylene molecules ranging from 1-5 nm in length. Molecules, based on 1-7, 9-11 paraxylene rings, have been synthesized as part of a homologous series of oligoparaxylenes (OPXs) with a view to providing a molecular tool box for the construction of nano architectures—such as spheres, cages, capsules, metal-organic frameworks (MOFs), metal-organic polyhedrons (MOPs) and covalent-organic frameworks (COFs), to name but a few—of well-defined sizes and shapes. Twisting between the planes of contiguous paraxylene rings is generated by the steric hindrance associated with the methyl groups and leads to the existence of soluble molecular gauge blocks without the need—at least in the case of the lower homologues—to introduce long aliphatic side chains onto the phenylene rings in the molecules.

Abstract: Compounds represented by general Formula I may form photo-responsive hydrogels that can be modulated between a non-viscous liquid state and a hydrogel. Formula I is: where a stereochemical conformation of double bond “a” is cis- or trans-, Ak is an alkylene group; and R represents a series of two or more naturally occurring or synthetic amino acid residues.

Abstract: Methods are disclosed for preparing compounds of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or where R6, R7 and R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. The methods can involve converting a suitably functionalized aniline compound to a diazonium salt (which aniline compound can be first formed by reduction of a nitrobenzene) and coupling the diazonium salt with a suitably functionalized benzene compound. The suitably functionalized aniline compound either includes a primary alcohol or aldehyde group, which is then oxidized to a carboxylic acid group, or includes a nitrile or amide group, which is hydrolyzed to a carboxylic acid group. The methods can also involve the direct coupling (via reduction of nitro groups to form an azo linkage) of suitably functionalized nitrobenzenes.

Abstract: The invention provides for a dye of the formula (I) where D is the residue of a diazo component; R1 is hydrogen, (C1-C6)-alkyl, (C1-C4)-alkoxy, hydroxyl, halogen, —NHCHO, —NHCO(C1-C6)-alkyl or —NHSO2(C1-C6)-alkyl; R2 is hydrogen, (C1-C6)-alkyl, (C1-C4)-alkoxy or halogen; R3 is hydrogen, (C1-C6)-alkyl, substituted (C1-C6)-alkyl, (C3-C4)-alkenyl or substituted (C3-C4)-alkenyl or R2 and R3 combine to form the radical —C*H(CH3)CH2C(CH3)2—, where the carbon atom marked * is attached to the phenyl nucleus; R4 is hydrogen or (C1-C6)-alkyl; R5 is hydrogen or (C1-C6)-alkyl; R6 is hydrogen or (C1-C6)-alkyl; X is phenyl, thiophenyl, sulfonylphenyl or phenoxy; n is 0 , 1, or 2; and m is 0 or 1. The invention is also related to the process of using the dye and the process of preparing the dye.

Abstract: Disperse dyes of the general formula (I) where D is a diazo component derived from a substituted or unsubstituted aromatic amine, K is an aromatic radical of the formula and the substituents are each as defined in the first claim. Further described are the preparation and the use of the dyes according to the invention.

Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

Abstract: A linker system is provided where a small molecule reactive group, e.g., an activity based probe which binds to certain enzymes at the active site, is linked through an aryl diazo linker to an affinity molecule such as biotin. The reactive group may comprise a number of functionalities known to react with a specific target to be studied. This enables the probe to be exposed to analytes, such as proteins and bind specifically to them to form a complex having an affinity molecule allowing immobilization of the bound analyte on an affinity column or other support, e.g. with streptavidin. Then, the linker is cleaved without causing removal of the affinity group or dissociation of the probe from the analyte. The linker is cleaved under mild reducing conditions, e.g., dithionite. The probe is synthesized along with the linker on a solid support.

Abstract: The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

Abstract: Quaternary boron salts are used as initiators of polymerisation in adhesive compositions for bonding low surface energy substrates such as polyolefins. The quaternary boron salts are of the formula I wherein R1 is C1-C10 alkyl, R2, R3 and R4, which may be the same or different, are, C1-C10 alkyl or C3-C10 cycloalkyl, phenyl, or phenyl-substituted C1-C10 alkyl or C3-C10 cycloalkyl, provided that any two of R1-R4 may optionally be part of a carbocyclic ring, and M+ is a metal ion or a quaternary ammonium ion. When M+ is a quaternary ammonium ion, the initiator may be used in a two-part composition having a (meth)acrylate monomer in both parts and the initiator compound in one part, the two parts being in a weight ratio of about 1:1.

Abstract: Compounds are disclosed having the structure of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or where R6, R7 and R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed: where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl, and R12 is selected from the group consisting of hydrogen and —C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group.

Abstract: Azo dyes of the formula wherein the substituents are each as defined in the description, are useful for dyeing and printing synthetic textile materials.

Abstract: The application describes a process for preparing 4-hydroxyanilines by the reaction of phenols with diazonium salts and subsequent reduction.

Abstract: The present invention provides a bis (aminocarbonylnaphthol) derivative which is useful as a raw material for novel azo pigments by bisamidation of each one carboxyl group of two 2-hydroxynaphthalene-3,6-dicarboxylic acids using an aliphatic or aromatic diamine.

Abstract: The azo dyes of the formula I ##STR1## where X.sup.1 is for example hydrogen or (C.sub.1 to C.sub.6)alkyl,X.sup.2 is cyano or nitro,X.sup.3 is for example hydrogen or (C.sub.1 to C.sub.4)alkoxy,X.sup.4 is for example (C.sub.1 to C.sub.4)alkoxy, chlorine or hydrogen,R.sup.1 is hydrogen or (C.sub.1 to C.sub.6)alkyl,R.sup.2 is hydrogen or (C.sub.1 to C.sub.6)alkyl andR.sup.3 is for example (C.sub.1 to C.sub.8)alkyl,are highly suitable for dyeing and printing hydrophobic fiber materials.

Abstract: A chromogenic compound found to be especially selective in the determination of calcium in blood of the general formula (I): ##STR1## where: R is hydrogen or lower alkyl;X is CH.sub.2, CH.sub.2 CH.sub.2, CH.dbd.CH, O, S, SO.sub.2, S--S, or NR;X is CH, C--OH or N;M is p-nitrophenylazo, 2,4-dinitrophenylazo, 2,4,6-trinitrophenylazo, p-nitrostyryl, p-benzoquinoneimino, bis-(4-dimethylaminophenyl) hydroxymethyl, 3-phenylisothiazolyl-5-azo, thiazolyl-5-azo, or isothiazolyl-5-azo;k is 1;l is 0 or 1; andn is 0 or 1.

Abstract: An azo compound of the formula: ##STR1## wherein R is an non-hydrophilic aliphatic or cycloaliphatic group containing from 8 to 40 carbon atoms;m is 0 or 1;R.sup.1 is NO.sub.2, CN or COOR.sup.2 ;R.sup.2 is H or C.sub.1-4 -alkyl;n is from 1 to 4 andR.sup.3 is H, a metal or a group containing a tetravalent N atom.The compound has non-linear optical properties which make it suitable for use in an optical element such as a waveguide, for altering the characteristics of light passing through the element.

Abstract: The invention concerns azo compounds of formula ##STR1## or a salt thereof, in which formula R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are each independently hydrogen or lower alkyl, R.sup.7 and R.sup.8 are each independently alkyl of 1 to 7 carbon atom or cycloalkyl of 5 to 7 carbon atoms optionally substituted by lower alkyl which possess anti-inflammatory activity.

Abstract: Described herein are novel substantially linear monomeric compositions which can be polymerized with one or more difunctional monomers to give novel polymeric compositions having liquid crystal properties. This invention is also directed to a process for preparation of the novel substantially linear monomeric compositions.

Abstract: This invention relates to a method for preparing 2-phenylbenzotriazoles having the formula I, ##STR1##

Abstract: (i) A compound of the formula: ##STR1## wherein R is H, a metal or a group containing a tetravalent N atom;X is S, O, ##STR2## R.sup.1 is NO.sub.2, CN or COOY; Y is H, C.sub.1-4 -alkyl, a metal or a group containing a tetravalent N atom;R.sup.2 and R.sup.3 are each independently H or a non-hydrophilic aliphatic or cycloaliphatic group containing up to 30 carbon atoms;R.sup.4 and R.sup.5 are each independently H or a non-hydrophilic aliphatic or cycloaliphatic group containing up to 30 carbon atoms; andR.sup.6 and R.sup.7 are each independently H or a non-hydrophilic group containing up to 4 carbon atoms; orR.sup.4 and R.sup.6 together comprise ring fused to Ring A and R.sup.5 and R.sup.7 are as hereinbefore defined; orR.sup.5 and R.sup.7 together comprise ring fused to Ring A and R.sup.4 and R.sup.6 are as hereinbefore defined; orR.sup.2 and R.sup.4 together with the N atom to which R.sup.2 is attached form a ring fused to Ring A and R.sup.3 and R.sup.5 are as hereinbefore defined; orR.sup.3 and R.sup.

Abstract: The present invention provides gamma-glutamyl-4-azoanilides, processes for their preparation and their use as substrates for gamma-glutamyl transferase determination, of the formula ##STR1## wherein X is alkyl, --(CH.sub.2).sub.m --COOH or --O--(CH.sub.2).sub.n --COOH wherein m is 0-4 and n is 1-4; R is optionally substituted p-nitrophenyl; an optionally substituted thiophene residue; an optionally substituted thiazole residue; an optionally substituted benzothiazole residue; an optionally substituted benzoisothiazole residue; an N-alkylthiazole residue; or an optionally substituted 1,3,5-thiodiazole residue; as well as the alkali metal, alkaline earth metal and ammonium salts thereof.

Abstract: The present invention is concerned with azo compounds having the structure ##STR1## in which: Y is hydrogen, andX and Z are carboxy or lower alkoxycarbonyl,or the lactones or salts of said azo compound, such compounds being useful in pharmaceutical compositions and being specifically useful to inhibit 15-prostaglandin dehydrogenase (PGDH).

Abstract: The invention relates to new arylazo compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 independently of each other represent hydrogen or C.sub.1-3 alkyl, R.sub.3 represents hydrogen, halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, carboxy, C.sub.1-3 alkoxycarbonyl, C.sub.1-3 alkylcarbonyl or a group X--NH--SO.sub.2 --, wherein X represents a heterocyclic ring, R.sub.4 represents hydrogen, halogen or C.sub.1-3 alkyl, and n is the integer 1 or 2, the two groups ##STR2## being the same or different when n is 2, and lactones and salts thereof. The compounds of formula I have a high inhibiting effect on prostaglandin synthetizing and inactivating enzymes and may therefore be used as a drug and anti-fertility agent. The invention also relates to preparation of the compounds of formula I as well as pharmaceutical compositions containing the same.